Description: Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in Australia and New Zealand. It is developing NTCELL, an alginate-coated capsule, which is in phase IIb clinical trial for the treatment of Parkinson's disease. The company was founded in 1987 and is based in Sydney, Australia.
Home Page: www.lctglobal.com
Tower 2
Sydney,
NSW
2000
Australia
Phone:
61 3 8689 9997
Officers
| Name | Title |
|---|---|
| Dr. Bernard Tuch B.Sc., BSc, FRACP, GAICD, MBBS, MBBS (Hons), Ph.D. | Interim Chief Exec. Officer |
| Mr. Daya Uka | Chief Financial Officer |
| Dr. Belinda Di Bartolo | Chief Operations Officer |
| Mr. Mark Andrew Licciardo B Bus (Acc), FCIS, FGIA, GAICD, GradDip CSP | Company Sec. |
Exchange: F
Country: DE
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.4668 |
| Price-to-Sales TTM: | 2950.6409 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |